Pila Pharma enrolls first participant in PP-CT04 obesity trial of XEN-D0501
Bitget2026/09/30 15:18- Pila Pharma launched dosing for Part 1 of PP-CT04, a 12-week obesity trial of oral candidate XEN-D0501.
- No clinical results have been presented; Part 2 is slated to start once Part 1 clears an internal safety review.
- The study aims to assess safety and tolerability, with additional readouts on drug exposure and efficacy.
- Part 1 uses an eight-participant pilot cohort with intensified safety monitoring before broader enrollment proceeds.
- Dosing uses individual titration to higher target exposures, seeking levels not previously tested in the program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Jefferies lowers target price for Antero Resources
Euro-area Inflation: Headline pressures rise – Nordea
Broadcom and Blackstone jointly raise $60 billions to pave the way for AI compute power for companies such as Anthropic
Broadcom is leading a $60 billion debt financing initiative to provide funding for AI companies such as Anthropic to purchase chips and build data centers. Of this amount, $42 billion in senior secured bonds will be syndicated by Broadcom with Wall Street banks, while $18 billion in subordinated debt is being led by Blackstone, whose funds have committed $9 billion. The deal has been in preparation for several weeks but has not yet been officially announced.
Crypto prices
More
